In vitro effects of lonidamine and 6-aminonicotinamide against Echinococcus granulosussensu stricto and Echinococcus
Qi Xin1, Miaomiao Yuan1,2, Huanping Li1
1Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Abstract:
Echinococcosis is a zoonotic disease caused by cestode species of the genus Echinococcus, which demonstrates considerable medical and veterinary concerns. The development of novel drugs for echinococcosis treatment is urgently needed. In this study, we demonstrated that lonidamine (LND) and 6-aminonicotinamide (6-AN) exhibited considerable in vitro effects against both larval- and adult-stage of E. granulosussensu stricto (s. s.) and E. multilocularis. The combination of LND and 6-AN exhibited a significantly higher activity than the single drug treatment. These results highlight the therapeutic potential of LND, 6-AN and the combination of LND and 6-AN for the treatment of echinococcosis.
Insights
Novel drugs lonidamine (LND) and 6-aminonicotinamide (6-AN) show promise for treating echinococcosis. Combining LND and 6-AN demonstrated significantly higher efficacy against Echinococcus parasites than individual treatments.
Area of Science:
- Parasitology
- Drug Discovery
- Zoonotic Diseases
Background:
- Echinococcosis is a significant zoonotic disease caused by Echinococcus cestodes, posing major medical and veterinary challenges.
- Current treatments for echinococcosis are limited, necessitating the development of new therapeutic agents.
Purpose of the Study:
- To evaluate the in vitro efficacy of lonidamine (LND) and 6-aminonicotinamide (6-AN) against Echinococcus parasites.
- To assess the combined therapeutic potential of LND and 6-AN for echinococcosis treatment.
Main Methods:
- In vitro testing of lonidamine (LND) and 6-aminonicotinamide (6-AN) against larval and adult stages of Echinococcus granulosus sensu stricto (s. s.) and Echinococcus multilocularis.
- Comparative analysis of single drug treatments versus a combination therapy.
Main Results:
- Both lonidamine (LND) and 6-aminonicotinamide (6-AN) exhibited significant in vitro activity against both larval and adult stages of E. granulosus s. s. and E. multilocularis.
- The combination of LND and 6-AN demonstrated markedly enhanced anti-parasitic activity compared to either drug administered alone.
Conclusions:
- Lonidamine (LND) and 6-aminonicotinamide (6-AN) show therapeutic potential for treating echinococcosis.
- Combination therapy with LND and 6-AN offers a promising strategy for more effective echinococcosis treatment.
